Comparison of the impact of pro- and antiinflammatory immune processes at the two immune-deviated sites, eye and solid tumor and possible consequences for the antitumoral therapy with fever inducers.
Findings from various epidemiological studies suggest that acute inflammation and fever may decrease the risk of developing certain types of cancer. In an established tumor situation acute inflammation and fever resulted in tumor regression in some cases, however, treatment was sometimes ineffective or even deleterious. It has been suggested that chronic inflammation contributes to carcinogenesis and in an established tumor situation to malignancy. In order to better understand the role of acute inflammation and fever in the treatment of cancer, we compare some of the current knowledge about the effects of pro- and antiinflammatory immunological processes in the two immune-deviated sites, eye and cancer. Striking similarities between these two sites have been demonstrated. The knowledge gained in experimental studies abrogating immune privilege in the eye could provide insights into the inconsistent results of proinflammatory cancer therapy. The eye could be used as a model to develop hypotheses on how to abolish the immunological tolerance state of a solid tumor and make it susceptible to immunological destruction. The immune privilege of the eye is abrogated, at least transiently, in the initial stages of tissue- or organ-specific cellular autoimmune responses and this effect is possibly supported by complement- fixing/proinflammatory antibodies. An overview of possible consequences for the tumor therapy especially in connection with inflammation and fever inducers such as bacterial vaccines or mistletoe preparations, which are therapeutically used to interfere with the privileged immune state of the tumor, is given.
Schramm
Henning
H
Weleda AG, Arlesheim, Schweiz. hschramm@weleda.ch
D000917:Antibody Formation; D015551:Autoimmunity; D001428:Bacterial Vaccines / Q000494:pharmacology / Q000627:therapeutic use; D002908:Chronic Disease; D005123:Eye / Q000276:immunology*; D005134:Eye Neoplasms / Q000276:immunology; D005334:Fever / Q000209:etiology / Q000276:immunology; D006801:Humans; D007111:Immunity, Cellular; D007249:Inflammation / Q000276:immunology*; D009369:Neoplasms / Q000209:etiology / Q000276:immunology* / Q000628:therapy*; D009928:Organ Specificity; D028321:Plant Preparations / Q000494:pharmacology / Q000627:therapeutic use; D010940:Plant Proteins / Q000494:pharmacology / Q000627:therapeutic use; D054790:Ribosome Inactivating Proteins, Type 2; D014118:Toxins, Biological / Q000494:pharmacology / Q000627:therapeutic use
D001428:Bacterial Vaccines; D028321:Plant Preparations; D010940:Plant Proteins; D054790:Ribosome Inactivating Proteins, Type 2; D014118:Toxins, Biological; C009674:ribosome inactivating protein, Viscum